Leuven, September 2, 2015 – Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the launch of a new website: www.oncurious.com
The new website provides more background on the compelling science behind the Company’s lead product TB-403 and its potential to improve the treatment of medulloblastoma, a rare life-threatening brain tumor that mainly affects children.
Oncurious NV is a joint venture between ThromboGenics and VIB, a leading life science research institute in Flanders (Belgium).
For further information please contact:
Oncurious NV / ThromboGenics NV:
Wouter Piepers
+32 16 75 13 10 / +32 478 33 56 32
wouter.piepers@thrombogenics.com
Citigate Dewe Rogerson
David Dible/Malcolm Robertson
Tel: +44 20 7638 9571
david.dible@citigatedr.co.uk
About Oncurious NV
Oncurious NV is an oncology company focused on the development of innovative medicines for the treatment of pediatric brain tumors. Oncurious is a joint venture between ThromboGenics and VIB, a leading life science research institute in Flanders (Belgium).
Oncurious plans to initiate a Phase I/IIa clinical program with TB-403 for the treatment of medulloblastoma, a rare, life-threatening brain tumor that mainly affects children. Enrolment of the first patient is expected by the end of 2015. BioInvent International is Oncurious’ co-development partner for the planned Phase I/IIa TB-403 clinical trial.
More information on Oncurious can be found at www.oncurious.com
Help employers find you! Check out all the jobs and post your resume.
The new website provides more background on the compelling science behind the Company’s lead product TB-403 and its potential to improve the treatment of medulloblastoma, a rare life-threatening brain tumor that mainly affects children.
Oncurious NV is a joint venture between ThromboGenics and VIB, a leading life science research institute in Flanders (Belgium).
For further information please contact:
Oncurious NV / ThromboGenics NV:
Wouter Piepers
+32 16 75 13 10 / +32 478 33 56 32
wouter.piepers@thrombogenics.com
Citigate Dewe Rogerson
David Dible/Malcolm Robertson
Tel: +44 20 7638 9571
david.dible@citigatedr.co.uk
About Oncurious NV
Oncurious NV is an oncology company focused on the development of innovative medicines for the treatment of pediatric brain tumors. Oncurious is a joint venture between ThromboGenics and VIB, a leading life science research institute in Flanders (Belgium).
Oncurious plans to initiate a Phase I/IIa clinical program with TB-403 for the treatment of medulloblastoma, a rare, life-threatening brain tumor that mainly affects children. Enrolment of the first patient is expected by the end of 2015. BioInvent International is Oncurious’ co-development partner for the planned Phase I/IIa TB-403 clinical trial.
More information on Oncurious can be found at www.oncurious.com
Help employers find you! Check out all the jobs and post your resume.
